BIOTRONIK has reported the first global implantation of its BIOMONITOR IV implantable cardiac monitor (ICM) that targets efficiency in monitoring cardiac arrhythmias.

BIOMONITOR IV is an advanced ICM that combines BIOTRONIK’s SmartECG technology with artificial intelligence (AI). It is claimed by the Germany-based medical device technology firm to minimise all false positive detections by 86% and save 98% of true episodes.

BIOTRONIK said that the implant is the only ICM that can differentiate between premature atrial contractions (PACs) and premature ventricular contractions (PVCs) to offer better tools for risk classification and diagnosis to healthcare specialists.

The first procedure with BIOMONITOR IV was conducted by Luigi Di Biase at Montefiore Einstein in the Bronx, New York.

Di Biase said: “I am excited about BIOMONITOR IV’s new algorithm and artificial intelligence. The data shows that these new features have the potential to reduce false positive alerts for our patients and allow us to focus on actionable events, providing more efficient care.”

Apart from advanced AI, the BIOMONITOR IV is said to have a long battery life and wireless connectivity to facilitate seamless data transmission and remote monitoring. This reduces the need for regular in-person clinic visits.

Additionally, BIOTRONIK has the simplest electronic health record (EHR) data integration capabilities, which can enhance clinic productivity, the medical technology firm added.

The introduction of BIOMONITOR IV ICM is said to align with the company’s dedication to innovation and enhancing patient care.

BIOTRONIK aims to advance the medical field with advanced technologies and empower healthcare professionals to improve the lives of patients.

The launch also strengthens BIOTRONIK’s position in the cardiac monitoring devices market, thus advancing cardiovascular medicine.

In April this year, the German firm secured the US Food and Drug Administration (FDA) approval for its spinal cord stimulation (SCS) system, Prospera.